Literature DB >> 19387007

Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic features of 9 cases.

Ilaria Del Giudice1, Sabina Chiaretti, Simona Tavolaro, Maria Stefania De Propris, Roberta Maggio, Francesca Mancini, Nadia Peragine, Simona Santangelo, Marilisa Marinelli, Francesca Romana Mauro, Anna Guarini, Robin Foà.   

Abstract

In chronic lymphocytic leukemia (CLL), spontaneous regressions are an exceptional phenomenon, whose biologic features are unknown. We describe 9 CLL patients who underwent a spontaneous clinical regression over an 11-year follow-up, despite a residual neoplastic clone detected by flow cytometry. CD38 and ZAP-70 were negative in all cases. Immunoglobulin heavy chain variable region (IgVH) genes, mutated in all 7 evaluable patients, were restricted to the VH3 family in 6, with the usage of V(H)3-30 gene in 2. The light chain variable region genes were mutated in 6 of 8 cases, with the use of V(kappa)4-1 gene in 3. Microarray analysis of CLL cells showed a distinctive genomic profile with an overrepresentation of BCR-related and ribosomal genes, regulators of signal transduction and transcription. The number of activated T lymphocytes expressing IFN-gamma, TNF-alpha, and IL-4 was similar between CLL in spontaneous regression and healthy persons. In conclusion, spontaneous clinical regressions can occur in CLL despite the persistence of the neoplastic clone, and the biologic features include negative CD38 and ZAP-70, mutated V(H)3-30 and V(kappa)4-1 genes. The peculiar gene profile suggests that BCR signaling may play an important role in this scenario as the most significant feature of the leukemic clone in regression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19387007     DOI: 10.1182/blood-2008-12-196568

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

Review 2.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

3.  Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Timothy G Call; Clive S Zent; Jose F Leis; Betsy LaPlant; Deborah A Bowen; Michelle Roos; Kristina Laumann; Asish K Ghosh; Connie Lesnick; Mao-Jung Lee; Chung S Yang; Diane F Jelinek; Charles Erlichman; Neil E Kay
Journal:  Cancer       Date:  2012-07-03       Impact factor: 6.860

4.  Reassessment of small lymphocytic lymphoma in the era of monoclonal B-cell lymphocytosis.

Authors:  Sarah E Gibson; Steven H Swerdlow; Judith A Ferry; Urvashi Surti; Paola Dal Cin; Nancy Lee Harris; Robert P Hasserjian
Journal:  Haematologica       Date:  2011-05-05       Impact factor: 9.941

5.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

6.  Comparative study of unsupervised dimension reduction techniques for the visualization of microarray gene expression data.

Authors:  Christoph Bartenhagen; Hans-Ulrich Klein; Christian Ruckert; Xiaoyi Jiang; Martin Dugas
Journal:  BMC Bioinformatics       Date:  2010-11-18       Impact factor: 3.169

7.  Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients.

Authors:  Egil S Blix; Jonathan M Irish; Anne Husebekk; Jan Delabie; Anne M Tierens; June H Myklebust; Arne Kolstad
Journal:  Br J Haematol       Date:  2012-10-09       Impact factor: 6.998

8.  Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.

Authors:  Mohini Rajasagi; Sachet A Shukla; Edward F Fritsch; Derin B Keskin; David DeLuca; Ellese Carmona; Wandi Zhang; Carrie Sougnez; Kristian Cibulskis; John Sidney; Kristen Stevenson; Jerome Ritz; Donna Neuberg; Vladimir Brusic; Stacey Gabriel; Eric S Lander; Gad Getz; Nir Hacohen; Catherine J Wu
Journal:  Blood       Date:  2014-06-02       Impact factor: 22.113

9.  CLL: Common Leukemia; Uncommon Presentations.

Authors:  Deepesh Lad; Pankaj Malhotra; Neelam Varma; Manupdesh Singh Sachdeva; Ashim Das; Radhika Srinivasan; Amanjit Bal; Alka Khadwal; Gaurav Prakash; Vikas Suri; Savita Kumari; Sanjay Jain; Subhash Varma
Journal:  Indian J Hematol Blood Transfus       Date:  2014-12-24       Impact factor: 0.900

10.  Current and emerging treatments for chronic lymphocytic leukaemia.

Authors:  Tadeusz Robak; Krzysztof Jamroziak; Pawel Robak
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.